Do analysts recommend CNTX or LSTA?

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,316.32%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is CNTX or LSTA more profitable?

Context Therapeutics' return on equity of -82.06% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Lisata Therapeutics N/A -116.08% -90.55%

Do analysts rate LSTA or GOSS?

Gossamer Bio has a consensus price target of $3.20, suggesting a potential upside of 1,464.79%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Do analysts rate LSTA or FTH?

Sensei Biotherapeutics has a consensus target price of $55.00, suggesting a potential upside of 59.33%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Sensei Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85

Is LSTA or FTH more profitable?

Lisata Therapeutics' return on equity of -116.08% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -116.08% -90.55% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Do analysts prefer APLM or LSTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation and earnings, APLM or LSTA?

Apollomics has higher revenue and earnings than Lisata Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 6.91 -$10.94M N/A N/A Lisata Therapeutics $170K 92.22 -$16.59M -$1.64 N/A

Is APLM or LSTA more profitable?

Apollomics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Lisata Therapeutics N/A -116.08% -90.55%

Do analysts prefer LSTA or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 334.15%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Lisata Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Lisata Therapeutics (LSTA) Competitors

$1.74 -0.02 (-1.14%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.75 +0.01 (+0.69%)

As of 08/25/2026 05:40 PM Eastern

Compare

LSTA vs. CNTX, GOSS, FTH, APLM, and DYAI

Should you buy Lisata Therapeutics stock or one of its competitors? Lisata Therapeutics's main competitors and comparable companies include Context Therapeutics (CNTX), Gossamer Bio (GOSS), Sensei Biotherapeutics (FTH), Apollomics (APLM), and Dyadic International (DYAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lisata Therapeutics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Context Therapeutics' return on equity of -82.06% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,316.32%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lisata Therapeutics has higher revenue and earnings than Context Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Lisata Therapeutics	$170K	92.22	-$16.59M	-$1.64	N/A

In the previous week, Lisata Therapeutics had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Context Therapeutics	Neutral
Lisata Therapeutics	Neutral

Context Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Summary

Context Therapeutics beats Lisata Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Lisata Therapeutics compare to Gossamer Bio?

Lisata Therapeutics (NASDAQ:LSTA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Gossamer Bio has a consensus price target of $3.20, suggesting a potential upside of 1,464.79%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Lisata Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

In the previous week, Gossamer Bio had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Lisata Therapeutics. Gossamer Bio's average media sentiment score of 0.42 beat Lisata Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Lisata Therapeutics	Neutral
Gossamer Bio	Neutral

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lisata Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Gossamer Bio	-235.00%	N/A	-112.04%

Lisata Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	92.22	-$16.59M	-$1.64	N/A
Gossamer Bio	$48.47M	0.99	-$170.37M	-$0.70	N/A

Summary

Gossamer Bio beats Lisata Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Lisata Therapeutics compare to Sensei Biotherapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 2 mentions for Lisata Therapeutics. Sensei Biotherapeutics' average media sentiment score of 0.43 beat Lisata Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lisata Therapeutics	Neutral
Sensei Biotherapeutics	Neutral

Lisata Therapeutics has higher revenue and earnings than Sensei Biotherapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	92.22	-$16.59M	-$1.64	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Lisata Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Sensei Biotherapeutics has a consensus target price of $55.00, suggesting a potential upside of 59.33%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Lisata Therapeutics' return on equity of -116.08% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Summary

Sensei Biotherapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Apollomics had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Apollomics and 2 mentions for Lisata Therapeutics. Apollomics' average media sentiment score of 0.62 beat Lisata Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
Lisata Therapeutics	Neutral

Apollomics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Lisata Therapeutics	N/A	-116.08%	-90.55%

Apollomics has higher revenue and earnings than Lisata Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	6.91	-$10.94M	N/A	N/A
Lisata Therapeutics	$170K	92.22	-$16.59M	-$1.64	N/A

Summary

Apollomics beats Lisata Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Lisata Therapeutics compare to Dyadic International?

Lisata Therapeutics (NASDAQ:LSTA) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Dyadic International has higher revenue and earnings than Lisata Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	92.22	-$16.59M	-$1.64	N/A
Dyadic International	$3.09M	8.15	-$7.36M	-$0.23	N/A

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Dyadic International had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.00 beat Dyadic International's score of -0.50 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Neutral
Dyadic International	Negative

Lisata Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Lisata Therapeutics' return on equity of -116.08% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 334.15%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lisata Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Summary

Dyadic International beats Lisata Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.86M	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-1.06	11.81	270.94	24.14
Price / Sales	92.22	1,381.12	634.76	96.68
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	1.96	16.86	13.14	6.25
Net Income	-$16.59M	-$22.76M	$3.46B	$347.86M
7 Day Performance	55.36%	1.84%	1.53%	0.98%
1 Month Performance	4.19%	12.26%	8.82%	5.24%
1 Year Performance	-30.68%	57.39%	26.07%	17.04%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	0.4905 of 5 stars	$1.74 -1.1%	N/A	-31.2%	$15.86M	$170K	N/A	30	Short Interest Increase
CNTX Context Therapeutics	2.1114 of 5 stars	$0.47 +0.9%	$6.17 +1,212.3%	-50.1%	$42.80M	N/A	N/A	7
GOSS Gossamer Bio	2.7349 of 5 stars	$0.18 -2.3%	$3.20 +1,701.8%	-91.3%	$42.67M	$48.47M	N/A	180	Gap Up
FTH Sensei Biotherapeutics	4.2315 of 5 stars	$29.38 -2.1%	$54.90 +86.9%	N/A	$40.26M	N/A	N/A	40
APLM Apollomics	2.4112 of 5 stars	$17.06 -6.1%	N/A	+322.0%	$39.88M	$8.50M	N/A	45	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. CNTX, GOSS, FTH, APLM, and DYAI

How does Lisata Therapeutics compare to Context Therapeutics?

Summary

How does Lisata Therapeutics compare to Gossamer Bio?

Summary

How does Lisata Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Lisata Therapeutics compare to Apollomics?

Summary

How does Lisata Therapeutics compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. CNTX, GOSS, FTH, APLM, and DYAI

How does Lisata Therapeutics compare to Context Therapeutics?

Is CNTX or LSTA more profitable?

Do analysts recommend CNTX or LSTA?

Do insiders and institutionals hold more shares of CNTX or LSTA?

Which has stronger earnings and valuation, CNTX or LSTA?

Does the media prefer CNTX or LSTA?

Which has more risk & volatility, CNTX or LSTA?

Summary

How does Lisata Therapeutics compare to Gossamer Bio?

Do analysts rate LSTA or GOSS?

Which has more risk and volatility, LSTA or GOSS?

Does the media refer more to LSTA or GOSS?

Do institutionals & insiders hold more shares of LSTA or GOSS?

Is LSTA or GOSS more profitable?

Which has stronger earnings & valuation, LSTA or GOSS?

Summary

How does Lisata Therapeutics compare to Sensei Biotherapeutics?

Do insiders & institutionals hold more shares of LSTA or FTH?

Does the media refer more to LSTA or FTH?

Which has better valuation & earnings, LSTA or FTH?

Which has more volatility and risk, LSTA or FTH?

Do analysts rate LSTA or FTH?

Is LSTA or FTH more profitable?

Summary

How does Lisata Therapeutics compare to Apollomics?

Do analysts prefer APLM or LSTA?

Does the media prefer APLM or LSTA?

Which has more volatility and risk, APLM or LSTA?

Do insiders and institutionals have more ownership in APLM or LSTA?

Is APLM or LSTA more profitable?

Which has stronger valuation and earnings, APLM or LSTA?

Summary

How does Lisata Therapeutics compare to Dyadic International?

Which has preferable valuation & earnings, LSTA or DYAI?

Do institutionals & insiders hold more shares of LSTA or DYAI?

Does the media refer more to LSTA or DYAI?

Is LSTA or DYAI more profitable?

Do analysts prefer LSTA or DYAI?

Which has more risk & volatility, LSTA or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools